iShares NASDAQ Biotechnology I...

NASDAQ: IBB
$132.03
+$0.59 (+0.4%)
Closing price August 8, 2022
Source: ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will...
Source: ThinkstockFed Chair Janet Yellen offered a bit of a surprise in her semiannual Monetary Policy Report in front of Congress on Tuesday. It may seem like a bit like Alan Greenspan’s moment...
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back and then some through April 15.
Source: Photo by Spencer Platt/Getty ImagesAny time a market peaks, investors and commentators talk about the expectations of a sell-off. The S&P 500 and Dow Jones Industrial Average peaked less than...
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top names rated Outperform...
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a perfect entry point for...
Source: ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But...
Source: Jon OggBiotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what investors need...
Source: Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get...
Source: Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the...
Source: ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) has had a great 2012. Actually, it has had a hell of a year with a gain of almost 40% year to date. When you compare this to the iShares Nasdaq...
Source: ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena...
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals...
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from...
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement date....